ライフサイエンスコーパス: rheumatoid arthritis

1 y arthritis, including spondyloarthritis and rheumatoid arthritis.

2 anagement of psoriasis, Crohn's disease, and rheumatoid arthritis.

3 mune diseases such as multiple sclerosis and rheumatoid arthritis.

4 s of cohort studies on adiposity and risk of rheumatoid arthritis.

5 atory rheumatic disease of the elderly after rheumatoid arthritis.

6 associations with polymyalgia rheumatica and rheumatoid arthritis.

7 thma, atherosclerosis, neuropathic pain, and rheumatoid arthritis.

8 ces to improve autoimmune conditions such as rheumatoid arthritis.

9 it as a potential therapeutic candidate for rheumatoid arthritis.

10 of autoimmune diseases such as psoriasis and rheumatoid arthritis.

11 fment genes ELMO1, DOCK2, and RAC1 linked to rheumatoid arthritis.

12 on as a central event in the pathogenesis of rheumatoid arthritis.

13 alent BTK inhibitor being evaluated to treat rheumatoid arthritis.

14 rious chronic inflammatory diseases, such as rheumatoid arthritis.

15 rities to those targeted in the treatment of rheumatoid arthritis.

16 vation of B cells derived from patients with rheumatoid arthritis.

17 une conditions primary biliary cirrhosis and rheumatoid arthritis.

18 ted with several autoimmune diseases such as rheumatoid arthritis.

19 o enhanced inflammatory responses and severe rheumatoid arthritis.

20 h their pain-relieving effect, in a model of rheumatoid arthritis.

21 eumatism (EULAR) classification criteria for rheumatoid arthritis.

22 with leukocyte composition in blood and with rheumatoid arthritis.

23 a variety of autoimmune diseases, including rheumatoid arthritis.

24 )CD4(+) T cells in synovium of patients with rheumatoid arthritis.

25 T cell dysregulation as a central problem in rheumatoid arthritis.

26 of these IgGs can be used as biomarkers for rheumatoid arthritis.

27 is associated with the inflammatory state of rheumatoid arthritis.

28 rders such as inflammatory bowel disease and rheumatoid arthritis.

29 or (uPAR) in joint tissue from patients with rheumatoid arthritis.

30 raits, such as the interleukin-27 pathway in rheumatoid arthritis.

31 esis of BI 653048, a compound active against rheumatoid arthritis.

32 orted nursing interventions in patients with rheumatoid arthritis.

33 factor alpha blocker currently used to treat rheumatoid arthritis.

34 f PRIME cells in 19 additional patients with rheumatoid arthritis.

35 and safety of upadacitinib in patients with rheumatoid arthritis.

36 fficacy and safety profiles, particularly in rheumatoid arthritis.

37 and is the recommended first-line agent for rheumatoid arthritis.

38 most commonly inflammatory bowel disease and rheumatoid arthritis.

39 losing spondylitis, and seronegative erosive rheumatoid arthritis.

40 d a fundamentally different immunobiology to rheumatoid arthritis.

41 uggesting that VR23 can be selective against rheumatoid arthritis.

42 al selective Janus kinase inhibitor to treat rheumatoid arthritis.

43 d address the concerns of people living with rheumatoid arthritis?

44 ute to chronic inflammatory diseases such as rheumatoid arthritis(1).

45 t predictors (hazard ratios) of failure were rheumatoid arthritis (2.36), late post-surgical infectio

46 The most common cause of secondary SS was rheumatoid arthritis (98.1%), followed by systemic lupus

47 .8; 95% confidence interval [CI] = 1.2-2.5), rheumatoid arthritis (adjusted OR = 1.7; 95% CI = 1.5-1.

48 Rheumatoid arthritis affects individuals commonly during

49 59, 95% CI: 0.39-0.87), or specifically with Rheumatoid Arthritis (aHR=0.64), Granulomatosis with Pol

50 cluding hypothyroidism, hyperthyroidism, and rheumatoid arthritis, also type-2 diabetes and osteoarth

51 disorders (VTE risk is 4.7% in patients with rheumatoid arthritis and 2.5% in those without), and inh

52 old has been used for decades to treat human rheumatoid arthritis and benefits from 70-y hindsight on

53 key mediator in autoimmune diseases such as rheumatoid arthritis and Crohn's disease.

54 view, we assess this evidence in relation to rheumatoid arthritis and depression, with a focus on inn

55 vity was detected in the synovial fluid from rheumatoid arthritis and gout patients.

56 lammatory reflex to significantly ameliorate rheumatoid arthritis and inflammatory bowel disease prov

57 reatment for human autoimmune disorders like rheumatoid arthritis and inflammatory bowel disease yet

58 eases such as cancer, inflammatory diseases (rheumatoid arthritis and inflammatory bowel disease), me

59 ental in many inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.

60 ed 16S rRNA samples for periodontal disease, rheumatoid arthritis and inflammatory bowel diseases, as

61 cal treatment of autoimmune diseases such as rheumatoid arthritis and lupus.

62 is pathway, is a target for the treatment of rheumatoid arthritis and multiple sclerosis and is re-em

63 reported in few diseases/conditions such as rheumatoid arthritis and oral cancer, there are no repor

64 nflammatory disorders of the bone, including rheumatoid arthritis and osteoarthritis.

65 o protect from pathological bone loss during rheumatoid arthritis and osteoporosis, whose pathogenesi

66 improved clinical outcomes for patients with rheumatoid arthritis and other chronic autoimmune diseas

67 cal tumor necrosis factor (TNF) responses in rheumatoid arthritis and other inflammatory diseases.

68 GWAS results correlated with the genetics of rheumatoid arthritis and psoriasis.

69 sly identified as the primary risk factor in rheumatoid arthritis and referred to as the "shared epit

70 prove diagnosis of depression in people with rheumatoid arthritis and shed light on mechanisms that c

71 ng for the use of belimumab in patients with rheumatoid arthritis and Sjogren's syndrome.

72 ons for, inflammatory arthritides, including rheumatoid arthritis and spondyloarthritis.

73 Apoptotic CD4(+) T cells from patients with rheumatoid arthritis and systemic lupus erythematosus we

74 ses, including systemic lupus erythematosus, rheumatoid arthritis and systemic sclerosis.

75 of various diseases such as atherosclerosis, rheumatoid arthritis and type 2 diabetes mellitus.

76 ardiovascular disease, 3 each on obesity and rheumatoid arthritis, and 2 on chronic kidney disease.

77 dical history included basal cell carcinoma, rheumatoid arthritis, and Barrett esophagus.

78 onset and progression of multiple sclerosis, rheumatoid arthritis, and breast cancer.

79 act of AMDs on systemic lupus erythematosus, rheumatoid arthritis, and devastating monogenic disorder

80 (IC)-associated diseases, including SLE and rheumatoid arthritis, and following IgG Fcgamma receptor

81 ch as autoimmune disorders (type 1 diabetes, rheumatoid arthritis, and multiple sclerosis) and cardio

82 36 family members are involved in psoriasis, rheumatoid arthritis, and pulmonary diseases.

83 immunodeficiency virus infection, psoriasis, rheumatoid arthritis, and systemic lupus erythematosus p

84 mune diseases, including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus.

85 in inflammatory diseases such as psoriasis, rheumatoid arthritis, and ulcerative colitis and neurolo

86 inhibitor (CAI) agents for the management of rheumatoid arthritis are reported.

87 Using rheumatoid arthritis as an example of T cell mediated di

88 the tracer in larger group of patients with rheumatoid arthritis, as is planned for the next phase o

89 h characterization of the synovial tissue in rheumatoid arthritis, as well as psoriatic arthritis and

90 ry disease (hypothyroidism, hyperthyroidism, rheumatoid arthritis) associated with radiotherapy.

91 This disease network portraits rheumatoid arthritis, asthma, atherosclerosis, pulmonary

92 being treated with natalizumab, and one with rheumatoid arthritis being treated with rituximab.

93 et inflammatory processes are used to manage rheumatoid arthritis, but have not translated well into

94 a previous familial linkage study of SLE and rheumatoid arthritis, but the association has not been e

95 n can ameliorate autoimmune diseases such as rheumatoid arthritis by modulation of the immune system.

96 In rheumatoid arthritis, C5orf30 expression is cell-specifi

97 diabetes, Crohn disease, ulcerative colitis, rheumatoid arthritis, celiac disease, psoriasis, and mul

98 isorders, such as atopic dermatitis, asthma, rheumatoid arthritis, colitis, and conjunctivitis, among

99 of TNF-alpha and IL-17A in a mouse model of rheumatoid arthritis (collagen-induced arthritis) and th

100 XCI-skew is increased in twins with Rheumatoid Arthritis compared to unaffected identical co

101 The RACAT (Rheumatoid Arthritis Comparison of Active Therapies) tri

102 e, synovial samples from human patients with rheumatoid arthritis contained CX(3)CR1(+)HLA-DR(hi)CD11

103 Genetics of rheumatoid arthritis contributes to biology and drug dis

104 pes were constructed for 213 AS cases and 46 rheumatoid arthritis controls using family data.

105 clinical applications including oncology and rheumatoid arthritis, could also be exploited in future

106 Patients with active rheumatoid arthritis despite stable methotrexate were ra

107 associated with numerous conditions such as rheumatoid arthritis, diabetes, systemic lupus erythemat

108 ly correlated with both clinical measures of rheumatoid arthritis disease activity and with synovial

109 ase-specific autoantibodies in patients with rheumatoid arthritis display a shift toward the pro-infl

110 vestigate the in vivo efficacy of auranofin (rheumatoid arthritis FDA-approved drug) in a CDI mouse m

111 channel expressed at the plasma membrane of rheumatoid arthritis fibroblast-like synoviocytes (RA-FL

112 nse to lipopolysaccharide challenge in human rheumatoid arthritis fibroblast-like synoviocytes.

113 anscriptional profiles 1 to 2 weeks before a rheumatoid arthritis flare.

114 Longitudinal genomic analysis of rheumatoid arthritis flares revealed PRIME cells in the

115 Studies in patients with rheumatoid arthritis have shown that the rituximab biosi

116 en overweight/obesity and risk of developing rheumatoid arthritis, however, the evidence is not entir

117 tor infliximab in ankylosing spondylitis and rheumatoid arthritis; however, concerns about such indic

118 ary or secondary panuveitis (HR = 4.21), and rheumatoid arthritis (HR = 3.30) were significantly asso

119 e and inflammatory-related diseases, such as rheumatoid arthritis, IgA nephropathy, ankylosing spondy

120 Inclusion criteria were (i) patients with rheumatoid arthritis, (ii) adult population age >/=16yea

121 ntally healthy, and did not have diabetes or rheumatoid arthritis in 2000.

122 ess the efficacy and safety of sirukumab for rheumatoid arthritis in a phase 3 study (SIRROUND-T).

123 mumab plus methotrexate for the treatment of rheumatoid arthritis in patients with a previous inadequ

124 (RRs) and 95% confidence intervals (CIs) for rheumatoid arthritis in relation to different measures o

125 filgotinib, and baricitinib in patients with rheumatoid arthritis, inflammatory bowel diseases, psori

126 Rheumatoid arthritis is a chronic autoimmune disease tha

127 Rheumatoid arthritis is a chronic autoimmune disease tha

128 Rheumatoid arthritis is a chronic autoimmune disorder re

129 Strikingly, progression to rheumatoid arthritis is associated with altered expressi

130 Rheumatoid arthritis is characterized by progressive joi

131 variety of physiological conditions such as rheumatoid arthritis, ischemia/reperfusion injury, strok

132 ches for various rheumatic diseases, such as rheumatoid arthritis, juvenile idiopathic arthritis, adu

133 Rheumatoid arthritis, like many inflammatory diseases, i

134 d in various pathological conditions such as rheumatoid arthritis, liver fibrosis, or obesity.

135 y, FcRn blockade decreased inflammation in a rheumatoid arthritis model without reducing circulating

136 27,161 persons under 65 years of age who had rheumatoid arthritis, multiple sclerosis, hepatitis C, p

137 Aberrant PAD activity is associated with rheumatoid arthritis, multiple sclerosis, lupus, and cer

138 1), inflammatory bowel disease (n = 27,739), rheumatoid arthritis (n = 25,324), systemic lupus erythe

139 In active rheumatoid arthritis, NOTCH3 and Notch target genes are

140 th autoimmune diseases other than SLE (e.g., rheumatoid arthritis or multiple sclerosis) or in sera f

141 ondylitis (OR = 0.72; 95% CI, 0.54-0.98) and rheumatoid arthritis (OR = 0.65; 95% CI, 0.50-0.84).

142 hinese, OR = 2.35 in European Americans) and rheumatoid arthritis (OR = 1.65 in Koreans).

143 r controls), individuals diagnosed with IBD, rheumatoid arthritis, or psoriasis after anti-TNFalpha i

144 ears) with inflammatory bowel disease (IBD), rheumatoid arthritis, or psoriasis and a primary cancer

145 ls from patients with acute Crohn's disease, rheumatoid arthritis, or sepsis were susceptible to both

146 ging evidence of the impact of infections on rheumatoid arthritis pathogenesis and flares.

147 wn to be effective in managing patients with rheumatoid arthritis, patient outcomes sensitive to nurs

148 Rheumatoid arthritis patients (n = 20) received single d

149 els of transmission in colorectal cancer and rheumatoid arthritis patients and, more generally, for s

150 of platelets with synovial fluid cells from rheumatoid arthritis patients reduced inflammatory cytok

151 ronounced in the primary synovial cells from rheumatoid arthritis patients than those from healthy do

152 disease-modifying antirheumatic drugs-naive rheumatoid arthritis patients was used to determine the

153 n synovial fibroblast-like synoviocytes from rheumatoid arthritis patients.

154 ynamics of iscalimab in healthy subjects and rheumatoid arthritis patients.

155 were suppressed in macrophages isolated from rheumatoid-arthritis patients, revealing a disease-assoc

156 Case 1: A 52-year-old Thai female with rheumatoid arthritis presented with scleritis.

157 chronic conditions such as atherosclerosis, rheumatoid arthritis, psoriasis, and Crohn's disease.

158 the treatment of chronic diseases, including rheumatoid arthritis, psoriasis, chronic pain, and hepat

159 era were derived from four large cohorts: 1) rheumatoid arthritis (RA) (n = 194, HD n = 64), 2) type

160 in the pathogenesis of systemic inflammatory rheumatoid arthritis (RA) and AD.

161 ible correlation of periodontal disease with rheumatoid arthritis (RA) and ankylosing spondylitis (AS

162 ds are frequently used for the management of rheumatoid arthritis (RA) and other chronic conditions,

163 e used extensively in clinical management of rheumatoid arthritis (RA) and other chronic inflammatory

164 umerous biologic agents for the treatment of rheumatoid arthritis (RA) and other forms of inflammator

165 s, including inflammatory arthritis, such as rheumatoid arthritis (RA) and psoriatic arthritis, perio

166 une-mediated inflammatory diseases including rheumatoid arthritis (RA) and spondyloarthritis (SpA).

167 the treatment of autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematos

168 ications for treating non-resistant malaria, rheumatoid arthritis (RA) and systemic lupus erythematos

169 cells are implicated in the pathogenesis of rheumatoid arthritis (RA) and TNF-alpha, a proinflammato

170 Patients with rheumatoid arthritis (RA) are at high risk of developing

171 Patients with rheumatoid arthritis (RA) are at increased risk for infe

172 ulatory mechanisms of drug-free remission in rheumatoid arthritis (RA) are unknown.

173 rthritis (LA), using osteoarthritis (OA) and rheumatoid arthritis (RA) as comparators.

174 The progressive debilitating nature of rheumatoid arthritis (RA) combined with its unknown etio

175 luster of differentiation 4 (CD4) T cells in rheumatoid arthritis (RA) develop remains poorly underst

176 Current treatments for rheumatoid arthritis (RA) do not reverse underlying aber

177 Monocytes in the context of rheumatoid arthritis (RA) exhibit increased CPP uptake a

178 g mRNAs and long non-coding RNA (lncRNAs) in rheumatoid arthritis (RA) fibroblast-like synoviocytes (

179 ed gene expression signatures to distinguish rheumatoid arthritis (RA) from non-inflammatory arthralg

180 ng (MRI) to guide treatment in patients with rheumatoid arthritis (RA) improves disease activity and

181 Pathogenic T cells in individuals with rheumatoid arthritis (RA) infiltrate non-lymphoid tissue

182 Rheumatoid arthritis (RA) is a chronic autoimmune diseas

183 Rheumatoid arthritis (RA) is a chronic autoimmune disord

184 Rheumatoid arthritis (RA) is a chronic immune-mediated d

185 Rheumatoid arthritis (RA) is a chronic inflammatory auto

186 Rheumatoid arthritis (RA) is a chronic inflammatory auto

187 Rheumatoid arthritis (RA) is a chronic inflammatory dise

188 Rheumatoid Arthritis (RA) is a chronic inflammatory diso

189 Rheumatoid arthritis (RA) is a common systemic inflammat

190 Rheumatoid arthritis (RA) is a debilitating and painful

191 Rheumatoid arthritis (RA) is an autoimmune disease chara

192 Rheumatoid arthritis (RA) is an inflammatory autoimmune

193 Rheumatoid arthritis (RA) is an inflammatory joint disea

194 The primary manifestation of rheumatoid arthritis (RA) is articular disease; however,

195 Rheumatoid arthritis (RA) is characterised by painful, s

196 Rheumatoid arthritis (RA) is closely associated with sha

197 Although joint pain in rheumatoid arthritis (RA) is conventionally thought to r

198 the increased risk of heart failure (HF) in rheumatoid arthritis (RA) is independent of ischemic hea

199 Rheumatoid arthritis (RA) is the most common immune-medi

200 l of recombinant human TRAIL in experimental rheumatoid arthritis (RA) models.

201 sent a considerable burden for patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA).

202 rs in healthy donors (HDs) and patients with rheumatoid arthritis (RA) or systemic lupus erythematosu

203 ave an important role in the pathogenesis of rheumatoid arthritis (RA) owing to their ability to gene

204 Rheumatoid arthritis (RA) patients have been observed to

205 on-invasive imaging of arthritis activity in rheumatoid arthritis (RA) patients using macrophage PET

206 This study sought to determine whether rheumatoid arthritis (RA) patients without active synovi

207 e of myocardial microvascular dysfunction in rheumatoid arthritis (RA) patients without clinical card

208 nt component C4d in pooled synovial fluid of rheumatoid arthritis (RA) patients.

209 status of this pathway in various stages of rheumatoid arthritis (RA) progression is unknown.

210 Many patients with rheumatoid arthritis (RA) report symptom relief from cer

211 Rheumatoid arthritis (RA) risk has a large genetic compo

212 The immunopathogenesis of rheumatoid arthritis (RA) spans decades, beginning with

213 Third, integration with rheumatoid arthritis (RA) summary statistics from Europe

214 Large meta-analyses of rheumatoid arthritis (RA) susceptibility in European (EU

215 tes (FLS), one of the main cell types of the rheumatoid arthritis (RA) synovium, possess phenotypic a

216 MK, 60 healthy controls and 35 patients with rheumatoid arthritis (RA) were included.

217 Rheumatoid arthritis (RA), a chronic inflammatory diseas

218 Rheumatoid arthritis (RA), a common autoimmune disease,

219 ree decades of advances in the management of rheumatoid arthritis (RA), a substantial minority of pat

220 Rheumatoid arthritis (RA), an autoimmune disease, has re

221 are the two most prevalent autoantibodies in rheumatoid arthritis (RA), and are thought to have disti

222 in actively inflamed joints of patients with rheumatoid arthritis (RA), and most animal models for RA

223 ohn's disease (CD), multiple sclerosis (MS), rheumatoid arthritis (RA), and others are increasingly r

224 Systemic diseases such as diabetes, rheumatoid arthritis (RA), and systemic lupus erythemato

225 In rheumatoid arthritis (RA), breakdown of self-tolerance a

226 diagnosis is critical to improve outcomes in rheumatoid arthritis (RA), but current diagnostic tools

227 code a "shared epitope" (SE) associated with rheumatoid arthritis (RA), especially more severe cyclic

228 In rheumatoid arthritis (RA), immunological triggers at muc

229 inated-peptide autoantibody) to diagnosis of rheumatoid arthritis (RA), including therapy-induced rem

230 ch as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), is increasingly recognised.

231 enosynovitis in the hands is associated with rheumatoid arthritis (RA), it is unknown whether tenosyn

232 diseases associated with osteolysis, such as rheumatoid arthritis (RA), often leading to disability i

233 fferentiate patients with FM from those with rheumatoid arthritis (RA), osteoarthritis (OA), or syste

234 In rheumatoid arthritis (RA), pathogenic T cells shift gluc

235 s specific for different forms of arthritis (rheumatoid arthritis (RA), psoriatic arthritis (PsA), os

236 kine in the inflamed joints of patients with rheumatoid arthritis (RA), together with compelling data

237 populations that drive joint inflammation in rheumatoid arthritis (RA), we applied single-cell RNA se

238 also been implicated in the pathogenesis of rheumatoid arthritis (RA), we evaluated the role of PON1

239 ng and deeply phenotyped patients with early rheumatoid arthritis (RA), we observe that peripheral bl

240 sted in a patient-derived in-vitro assay for Rheumatoid arthritis (RA), which yielded 5 promising gen

241 hat anti-neutrophil extracellular trap (NET) rheumatoid arthritis (RA)-rmAbs derived from CD19(+) B c

242 atus may indicate immunological remission in rheumatoid arthritis (RA).

243 ronmental risk factor for the development of rheumatoid arthritis (RA).

244 are postulated to be central in seropositive rheumatoid arthritis (RA).

245 damaged cells serves as a key autoantigen in rheumatoid arthritis (RA).

246 rovide the strongest genetic contribution to rheumatoid arthritis (RA).

247 s and miR-155 are increased in patients with rheumatoid arthritis (RA).

248 that has a long-recognized association with rheumatoid arthritis (RA).

249 well-known extra-articular manifestation of rheumatoid arthritis (RA).

250 ng pathways causing synovial inflammation in rheumatoid arthritis (RA).

251 etermine the osteoclastogenic role of H4R in rheumatoid arthritis (RA).

252 nercept-methotrexate in patients with active rheumatoid arthritis (RA).

253 is a proinflammatory cytokine implicated in rheumatoid arthritis (RA).

254 s has been implicated in the pathogenesis of rheumatoid arthritis (RA).

255 riasis (PsO), psoriatic arthritis (PsA), and rheumatoid arthritis (RA).

256 ) are present in two-thirds of patients with rheumatoid arthritis (RA).

257 py ameliorates disease in many patients with rheumatoid arthritis (RA).

258 thesised to affect type 1 diabetes (T1D) and rheumatoid arthritis (RA).

259 nflammatory drug primarily used for treating rheumatoid arthritis (RA).

260 play a critical role in the pathogenesis of rheumatoid arthritis (RA).

261 ltiomics data for classification accuracy of rheumatoid arthritis (RA).

262 M AAbs) present in the sera of patients with rheumatoid arthritis (RA).

263 e development of autoimmune diseases such as rheumatoid arthritis (RA).

264 ding chronic inflammatory conditions such as rheumatoid arthritis (RA); however, it has only been dur

265 cupation of farming has been associated with rheumatoid arthritis (RA); pesticides may account for th

266 ients with multiple sclerosis (MS, n = 147), rheumatoid arthritis (RA, n = 229), Crohn's disease (n =

267 control subjects (n = 76) and patients with rheumatoid arthritis (RA, n = 244).

268 The JAK inhibitor baricitinib, used to treat rheumatoid arthritis, reduces inflammation by modifying

269 ll costimulation modulator, in patients with rheumatoid arthritis refractory to biologic disease-modi

270 In patients with rheumatoid arthritis refractory to biologic DMARDs, upad

271 Lung complications are a major cause of rheumatoid arthritis-related mortality.

272 circumference were associated with increased rheumatoid arthritis risk, suggesting adiposity could be

273 es in PSs for coronary artery disease (CAD), rheumatoid arthritis, schizophrenia, waist-hip ratio (WH

274 losing spondylitis, polymyositis, psoriasis, rheumatoid arthritis, sicca syndrome, and systemic lupus

275 ce ratio [SIR]8.14), scleroderma (SIR 7.00), rheumatoid arthritis (SIR5.96), stillbirth (SIR4.50), an

276 is of three types of inflammatory arthritis: rheumatoid arthritis, spondyloarthritis and systemic juv

277 re similar to those in previous upadacitinib rheumatoid arthritis studies.

278 of patients with rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, syst

279 the sublining undergoes a major expansion in rheumatoid arthritis that is linked to disease activity(

280 In rheumatoid arthritis the synovial tissue undergoes marke

281 In rheumatoid arthritis, the target of the immune response

282 PRIME, cells in the blood from patients with rheumatoid arthritis; these cells shared features of inf

283 tion) has a principal role in progression of rheumatoid arthritis through generation of autoantibodie

284 ed home collection of blood in patients with rheumatoid arthritis to allow for longitudinal RNA seque

285 trepton, constituting a potential target for rheumatoid arthritis treatment.

286 The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to asse

287 ed in many human diseases, such as fibrosis, rheumatoid arthritis, tumor angiogenesis, and metastasis

288 ons in humans, including multiple sclerosis, rheumatoid arthritis, type-I diabetes, and cancer.

289 jacent to GAK, HLA-DRB5, LRRK2, and MAPT for rheumatoid arthritis, ulcerative colitis and Crohn disea

290 d from the joints of patients suffering from rheumatoid arthritis underwent a GM-CSF-independent necr

291 on between all NNAI disorders and psychosis; rheumatoid arthritis was examined separately given the w

292 In addition, a patient with early rheumatoid arthritis was studied with both (68)Ga-DOTA-S

293 With a focus on rheumatoid arthritis, we sought new insight into genetic

294 metatarsophalangeal joints was specific for rheumatoid arthritis when compared with findings in pati

295 collagen-induced arthritis, a mouse model of rheumatoid arthritis, which is associated with normalisa

296 volvement of Foxo3 in osteoclastogenesis and rheumatoid arthritis, which prompted us to further inves

297 irheumatic drugs (csDMARDs) in patients with rheumatoid arthritis who had an inadequate response to D

298 A 54-year-old white woman with a history of rheumatoid arthritis who was taking glucocorticoids and

299 INTERPRETATION: In patients with active rheumatoid arthritis who were refractory or intolerant t

300 ccessful treatment of multiple sclerosis and rheumatoid arthritis with anti-CD20 monoclonal antibodie